BioCentury
ARTICLE | Clinical News

IdeS: Ph II discontinued

January 27, 2017 4:35 AM UTC

Hansa discontinued an open-label, U.K. Phase II trial evaluating a single IV dose of IdeS after preliminary data from 2 asymptomatic patients with acquired TTP showed a "non-favorable" risk-benefit pr...

BCIQ Company Profiles

Hansa Biopharma AB

BCIQ Target Profiles

Immunoglobulin G (IgG)